Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of ...

– Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson’s and Alzheimer’s – Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a new composition of matter patent has been allowed by the United States Patent ...
Good morning all and thank you for joining us today for our FY22 Annual General Meeting. I’m pleased to share with you my chairman’s address for this year’s Annual General Meeting for Alterity Therapeutics. We are hosting this meeting both in person in Melbourne and virtually, to ensure all of our shareholders and corporate partners ...
AGM 2022 Presentation
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the American Autonomic Society (AAS) 2022 Annual Conference held November 2-5, ...
First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and Australia Approval of Investigational New Drug application by FDA to bring the Phase 2 clinical trial to the United States Data from bioMUSE study provides a quantitative measurement of MSA progression Cash balance on 30 September 2022 ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at the 147th Annual Meeting of the American Neurological Association (ANA) on ...
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received approval in Australia from the St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) to conduct the ...
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to allow evaluation ...
Phase 2 clinical trial for ATH434 commences in New Zealand and patient enrolment begins Regulatory approval from the U.K. and Italian regulatory agencies to proceed with the Phase 2 trial A$4.1 million R&D Tax Incentive Scheme refund Cash balance on 30 June 2022 of A$34.8M MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 22 July 2022. ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder. While it is similar ...
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$4.1 million cash refund from the Australian Taxation Office under the Australian Government’s R&D Tax Incentive Scheme. The cash refund relates to the cost of ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in investor meetings at the Benchmark Company Healthcare House Call Conference.The conference is taking place virtually on Thursday, 2 June 2022. About ...
Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disorder Society Congress. Expanded intellectual property portfolio positions future opportunities. Cash balance as of 30 September 2021 of A$41.3M. Quarterly operating cash outflow of $4.9M as expected and in-line with clinical trial activity. Alterity Therapeutics Limited ...
Highlights: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 31 January 2023. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2022 (Q2 ...
Independent Study Reports ATH434 Prevented Onset of Motor and Non-Motor Symptoms in Animals with Genetically Induced Parkinson’s disease Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead ...
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian Disorder Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System ...
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now ...
Receive news from Alterity Therapeutics
